$1.48
−0.67%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.50
From 52W high−77.30%
Volume81010.00
Market cap$150.72M
P/E (TTM)—
P/S (TTM)5.8x
Div yield—
Key dataSep 18, 2026
Open
$1.50
From 52W high
−77.30%
Volume
81010.00
Market cap
$150.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
43.8
MomentumView details →
1D Return
−0.67%
YTD Return
−67.83%
SummaryUpdated Jun 1, 2026
Nyxoah S.A. (NASDAQ:NYXH) is a Belgian medical technology company founded in 2009 and headquartered in Mont-Saint-Guibert, Belgium. The company went public on NASDAQ in April 2021, focusing on developing innovative solutions for sleep-disordered breathing conditions. Nyxoah has established itself as a challenger in the hypoglossal nerve stimulation market, primarily competing against established players like Inspire Medical Systems. The company has achieved commercial success in Europe, particularly Germany, and is preparing for its U.S. market launch following anticipated FDA approval in early 2025.
Similar companies
Latest newsMore news →
Nyxoah announced the first patient implant in the BREATHE U.S. post-approval study of its Genio system, marking the start of the study's clinical rollout.13d agoNyxoah reported financial and operating results for the second quarter and first half of 2026, with U.S. net revenue of €5.2 million and global net revenue of €7.7 million for Q2 2026.46d ago